ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2023, 'Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial', The Lancet Digital Health, 5, pp. e679 - e691, http://dx.doi.org/10.1016/S2589-7500(23)00130-9
,2022, 'Long-term follow-up of epidermolysis bullosa in real practice shows stability of the Epidermolysis Bullosa Disease Activity and Scarring Index and improvement with some off-label therapies', JAAD International, 9, pp. 105 - 107, http://dx.doi.org/10.1016/j.jdin.2022.07.008
,2022, 'Primary cutaneous CD8+ aggressive epidermotropic T-cell lymphoma mimicking pyoderma gangrenosum', Indian Journal of Dermatology, Venereology and Leprology, 88, pp. 90 - 92, http://dx.doi.org/10.25259/IJDVL_296_2021
,2021, 'Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma', Journal of the European Academy of Dermatology and Venereology, 35, pp. 1519 - 1527, http://dx.doi.org/10.1111/jdv.17189
,2021, 'A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)', JAAD International, 2, pp. 134 - 152, http://dx.doi.org/10.1016/j.jdin.2020.12.007
,2021, '157 A comparison study of Outcome Measures for Epidermolysis Bullosa; Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)', Journal of Investigative Dermatology, 141, pp. S28 - S28, http://dx.doi.org/10.1016/j.jid.2021.02.177
,2020, 'Considerations in pre-treatment testing for Strongyloides stercoralis in an Australian cohort of 159 patients receiving biological therapies', Australasian Journal of Dermatology, 61, pp. 378 - 379, http://dx.doi.org/10.1111/ajd.13317
,2020, 'Successful dapsone therapy in inherited epidermolysis bullosa', Journal of the European Academy of Dermatology and Venereology, 34, pp. e333 - e334, http://dx.doi.org/10.1111/jdv.16301
,2020, 'Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma', Australasian Journal of Dermatology, 61, pp. 176 - 177, http://dx.doi.org/10.1111/ajd.13205
,2019, 'Mycobacterium chelonae infection mimicking demodex folliculitis.', Clin Exp Dermatol, http://dx.doi.org/10.1111/ced.14132
,2019, 'Is it psoriasis, a virus, or fungal infection?', Australian Doctor
,2009, 'Internet treatment for social phobia reduces comorbidity', Australian and New Zealand Journal of Psychiatry, 43, pp. 754 - 759
,2021, 'An exophytic penile mass', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY, pp. 61 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000630901700147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Mycobacterium chelonae infection mimicking demodex folliculitis', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000630901700145&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'A comparison study of Outcome Measures for Epidermolysis Bullosa; Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)', in JOURNAL OF INVESTIGATIVE DERMATOLOGY, ELSEVIER SCIENCE INC, Vol. 141, pp. S28 - S28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000641872800157&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Successful dapsone therapy in inherited Epidermolysis Bullosa', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY, Vol. 62, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000630901700144&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Which outcome measures are the best for clinical trials in Epidermolysis Bullosa?', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY, Vol. 62, pp. 110 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000630901700273&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'WHICH OUTCOME MEASURES ARE THE BEST FOR CLINICAL TRIALS IN EPIDERMOLYSIS BULLOSA?', in ACTA DERMATO-VENEREOLOGICA, ACTA DERMATO-VENEREOLOGICA, Vol. 100, pp. 38 - 39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568327600106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,